Read + Share
Mizuashi M. Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in
Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic. Acta Derm Venereol 2025;105:adv43616.
PMID: 40932280
|
 |
|
Mizuashi M. Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in
Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic. Acta Derm Venereol 2025;105:adv43616.
PMID: 40932280
|
|
|
|